Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

20776 Press Releases
DateTitleCompany
23 Jun 18 Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care Published by
GlobeNewswire
23 Jun 18 Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial Novo Nordisk A/S,
Published by
GlobeNewswire
23 Jun 18 Ozempic® provided greater weight reductions for adults with a baseline BMI of or above 25 kg/m2 than those with lower baseline BMI <25 kg/m2, in a SUSTAIN 7 post-hoc analysis Novo Nordisk A/S,
Published by
GlobeNewswire
23 Jun 18 Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA) Zealand Pharma,
Published by
GlobeNewswire
23 Jun 18 Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study Novo Nordisk A/S,
Published by
GlobeNewswire
23 Jun 18 Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions Zealand Pharma,
Published by
GlobeNewswire
23 Jun 18 Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications Novo Nordisk A/S,
Published by
GlobeNewswire
23 Jun 18 Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial Published by
GlobeNewswire
23 Jun 18 Ozempic® provided greater weight reductions for adults with a baseline BMI of or above 25 kg/m2 than those with lower baseline BMI <25 kg/m2, in a SUSTAIN 7 post-hoc analysis Published by
GlobeNewswire
23 Jun 18 Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA) Published by
GlobeNewswire
23 Jun 18 Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study Published by
GlobeNewswire
23 Jun 18 Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions Published by
GlobeNewswire
23 Jun 18 MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions Published by
GlobeNewswire
23 Jun 18 Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes Published by
GlobeNewswire
23 Jun 18 Dr. John R. Burroughs of Springs Aesthetics Now Offering vFit PLUS Feminine Wellness Treatment Device Dr. John R. Burroughs,
Published by
PR Newswire
23 Jun 18 One Third of Participants in a Workforce Study Reduce Risk for Diabetes after Employer Wellness Screening and Behavioral Counseling, Finds Quest Diagnostics Study Quest Diagnostics,
Published by
PR Newswire
23 Jun 18 Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study Novo Nordisk Canada Inc.,
Published by
PR Newswire
23 Jun 18 New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes Eli Lilly and Company,
Published by
PR Newswire
23 Jun 18 Fractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestine's Role in Type 2 Diabetes and NASH Fractyl Laboratories Inc.,
Published by
PR Newswire
23 Jun 18 Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients Janssen Pharmaceutical Companies,
Published by
PR Newswire
23 Jun 18 Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications Published by
GlobeNewswire
23 Jun 18 BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand Published by
GlobeNewswire
23 Jun 18 Investigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes Eli Lilly and Company,
Published by
PR Newswire
23 Jun 18 Two-year Data from ViaCyte's STEP ONE Clinical Trial Presented at ADA 2018 ViaCyte, Inc.,
Published by
PR Newswire
23 Jun 18 Xcode Life Announces the South Asian Genome (SAGE) Project Xcode Life,
Published by
PR Newswire
23 Jun 18 Women's Excellence Treats the Whole Woman During Menopause Women's Excellence,
Published by
PR Newswire
23 Jun 18 Women's Excellence Now Offers Solutions To Infertility Associated with Endometriosis Women's Excellence,
Published by
PR Newswire
23 Jun 18 Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available Medtronic plc,
Published by
GlobeNewswire
23 Jun 18 Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available Published by
GlobeNewswire
22 Jun 18 Healthcare Special Opportunities Fund Announces June 2018 Quarterly Distribution Published by
GlobeNewswire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.